Baylor College of Medicine researchers report in Science Advances that CS18, an experimental drug targeting TopBP1, a regulator of multiple cancer pathways, may help tumors that have grown resistant to therapy. Early evidence shows it strengthened existing treatments, restored sensitivity in resista